Furthermore, recent findings suggest that in breast cancer, the miR-100 may act as a pro-differentiating agent for cancer stem cell modulating Wnt/β-catenin pathway and Polo-like kinase 1 gene. The gene discussed is PLK1; the disease is breast carcinoma.